Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 19/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1005444 | 1.00 | HTR3A (0.49) | HTR3AKCNH2CYP2C19ALDH1A1HPGD | |
| Lithium Ion SCHEMBL1005443 | 0.90 | HTR3A (0.49) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL1005222 | 0.87 | HTR3A (0.47) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL3981326 | 0.87 | HTR3A (0.47) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL1006526 | 0.86 | HTR3A (0.45) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL1006450 | 0.86 | HTR3A (0.45) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL1005424 | 0.86 | HTR3A (0.47) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL1003499 | 0.86 | HTR3A (0.47) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL4409888 | 0.86 | HTR3A (0.47) | HTR3AKCNH2CYP2C19 | |
| SCHEMBL1006765 | 0.85 | HTR3A (0.51) | HTR3AKCNH2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863271-B2 | 2-aminobenzoxazole carboxamides as 5HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| EP-2061460-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | Albany Molecular Research, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008019372-A2 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255114-A1 | 2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | HTR3A 3/4885KCNH2 1871/4885CYP2C19 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.